FDA Launches Major Push for New Antimicrobials

The critical need for new medicines to combat infectious diseases that fail to respond to current medical treatment is prompting FDA to join with other federal health agencies and the biomedical research community to advance the science, regulatory policies and reimbursement strategies to suppor Powered by WPeMatico Continue reading FDA Launches Major Push for New Antimicrobials

States Expand Transparency & Disclosure Requirements

Just as biopharma companies are mastering the complexities of the five-year-old federal Open Payments program, state governments are enacting a host of additional marketing and disclosure rules and restrictions on industry interactions with health care professionals (HCPs). This stepped-up actio Powered by WPeMatico Continue reading States Expand Transparency & Disclosure Requirements

Piecing Together the Pricing Puzzle: The Midterm Elections

There is no magic bullet that will dramatically impact drug pricing to everybody s liking patients, industry, and government. But a stepwise approach involving a series of changes, including taking advantage of the next midterm elections, could point the path toward a solution Powered by WPeMatico Continue reading Piecing Together the Pricing Puzzle: The Midterm Elections

More New Drugs and Generics Reshape Pharma Markets

Amidst all the outrage over surging pharma prices, the continued growth in generic drug prescribing has moderated overall spending on medicines, cooling the political heat on industry. Generics now account for nearly 90% of prescription drug use in the US due to policies facilitating their devel Powered by WPeMatico Continue reading More New Drugs and Generics Reshape Pharma Markets